Loading patent…
AssigneeThe Regents of the University of California
InventorsSalvatore Albani, Berent Prakken
Estimating the term…
Provided are HLA pan DR-binding peptides and methods of using such peptides to modulate, block, or inhibit immune responses to effect treatment of immune-mediated diseases and conditions, such as inflammatory and autoimmune diseases, cancer, and microbial infections. These peptides and methods are also useful diagnostically to screen peptide or peptide analogs that can inhibit the pathogenic immune response or up-regulate an immune response against aberrant or invading cells, to monitor efficacy for therapeutic treatments, and to identify other agents that may be effective to inhibit or otherwise modulate an immune response such as by altering T cell functional phenotype, and even more particularly by modulating the regulatory phenotype of regulatory T cells and/or inducing emergence of T cells with a different functional phenotype.
A substantially pure HLA pan DR-binding peptide comprising a fragment of a stress protein that binds to one or more MHC class II molecules, wherein said peptide comprises an amino acid sequence that is at least 70% identical to a sequence selected from the group consisting of SEQ ID NOS:
An expression vector that directs the expression of a HLA pan DR-binding peptide that comprises a fragment of a stress protein that binds to one or more MHC class II molecules, wherein said peptide comprises an amino acid sequence that is at least 70% identical to a sequence selected from the group consisting of SEQ ID NOS:
An immunomodulating composition that comprises a pharmaceutically acceptable carrier and a substantially pure peptide comprising a fragment of a stress protein that binds to one or more MHC class II molecules.
A method for treating or preventing an immune-mediated disease in a subject having or at risk of having a disease comprising administering to the subject an effective amount of a composition comprising a pharmaceutically acceptable carrier and a substantially pure HLA pan DR-binding peptide that comprises a fragment of a stress protein that binds to one or more MHC class II molecules, wherein said peptide comprises an amino acid sequence that is at least 70% identical to a sequence selected from the group consisting of SEQ ID NOS:
A method of treating an immune-mediated disease, comprising administering to a patient having or at risk of contracting an immune-mediated disease an amount of an immune-modulating compound sufficient to modulate a regulatory phenotype of a population of regulatory T cells.
A method of treating an immune-mediated disease, other than rheumatoid arthritis, comprising administering to a patient having or at risk of contracting an immune mediated disease an amount of an immune-modulating compound sufficient to modulate a regulatory phenotype of a population of regulatory T cells, wherein the immune-modulating compound is other than a dnaJp1 peptide.
A method of screening to identify an immune-modulating compound, comprising (a) contacting a population of regulatory T cells with a test compound under suitable assay conditions and (b) assessing whether a regulatory phenotype of the population of regulatory T cells is modulated by step (a), and, if so, identifying the test compound as an immune-modulating compound.
Dependencies are inferred from the claim text.